ENTRADA THERAPEUTICS, INC. Revenue
ENTRADA THERAPEUTICS, INC. (TRDA) reported Revenue of $898.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $898.00K, a 53.95% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $875.00K, a 95.74% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $1.30M, a 96.53% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $1.61M, a 91.75% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $25.42M, a 87.94% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $210.78M, a 63.38% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $129.01M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $898.00K 10-Q · filed 2026-08-05 | $1.77M 10-Q · filed 2026-08-05 | $3.07M derived: sum of 3 quarters · filed 2026-08-05 | $4.69M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $875.00K 10-Q · filed 2026-05-07 | $2.17M derived: sum of 2 quarters · filed 2026-05-07 | $3.79M derived: sum of 3 quarters · filed 2026-05-07 | $5.74M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.91M derived: sum of 2 quarters · filed 2026-02-26 | $4.86M derived: sum of 3 quarters · filed 2026-08-05 | $25.42M 10-K · filed 2026-02-26 |
| 2025-09-30 | $1.61M 10-Q · filed 2025-11-06 | $3.56M derived: sum of 2 quarters · filed 2026-08-05 | $24.12M 10-Q · filed 2025-11-06 | $61.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $1.95M 10-Q · filed 2026-08-05 | $22.51M 10-Q · filed 2026-08-05 | $59.91M derived: sum of 3 quarters · filed 2026-08-05 | $79.48M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $20.56M 10-Q · filed 2026-05-07 | $57.96M derived: sum of 2 quarters · filed 2026-05-07 | $77.53M derived: sum of 3 quarters · filed 2026-05-07 | $172.22M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $37.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $56.97M derived: sum of 2 quarters · filed 2026-02-26 | $151.66M derived: sum of 3 quarters · filed 2026-02-26 | $210.78M 10-K · filed 2026-02-26 |
| 2024-09-30 | $19.57M 10-Q · filed 2025-11-06 | $114.26M derived: sum of 2 quarters · filed 2025-11-06 | $173.38M 10-Q · filed 2025-11-06 | $215.23M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $94.69M 10-Q · filed 2025-08-06 | $153.81M 10-Q · filed 2025-08-06 | $195.66M derived: sum of 3 quarters · filed 2025-08-06 | $239.40M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $59.12M 10-Q · filed 2025-05-08 | $100.97M derived: sum of 2 quarters · filed 2025-05-08 | $144.70M derived: sum of 3 quarters · filed 2025-05-08 | $162.87M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $41.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $85.58M derived: sum of 2 quarters · filed 2025-02-27 | $103.75M derived: sum of 3 quarters · filed 2025-02-27 | $129.01M 10-K · filed 2025-02-27 |
| 2023-09-30 | $43.73M 10-Q · filed 2024-11-05 | $61.91M derived: sum of 2 quarters · filed 2024-11-05 | $87.17M 10-Q · filed 2024-11-05 | |
| 2023-06-30 | $18.17M 10-Q · filed 2024-08-13 | $43.43M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $25.26M 10-Q · filed 2024-05-07 | |||
| 2022-09-30 | $0.00 10-Q · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |